DYAX: Dyax Corp. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DYAX: Dyax Corp.

DYAX 38.41

0.0%

Jan 25 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (37)	4/10/2002 6:34:54 PM
From: nigel bates	of 197

CAMBRIDGE, Mass.--(BW HealthWire)--April 10, 2002--Dyax Corp. (Nasdaq: DYAX - news) announced today that it has now granted over 60 Licenses to its phage display patent portfolio. A proprietary and patented method, phage display is used to identify a broad range of compounds with the potential to treat a variety of diseases. Dyax and its licensees and collaborators have also used phage display technology to identify compounds that can be used in diagnostic imaging, the development of research reagents, and in purifying and manufacturing biopharmaceuticals and chemicals. Among the 60 licensees are leading pharmaceutical and biotechnology companies as well as early stage companies and academic institutions. Enchira Biotechnology of The Woodlands, Texas is Dyax's most recent licensee...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next